毕业于克兰菲尔德大学的经济学博士陈舜如目前已经入职暨南大学产业经济研究院，"对大湾区科研人才引进方面的政策很心动！未来计划聚焦低 空经济、人工智能等产业领域进一步开展研究"。 "只要你敢想，只要你敢为，欢迎来到广州知识城，这就是创新实践的力量！"8月20日，此前作为《最强大脑》选手走红、刚刚从牛津大学工程系 自动化组博士毕业的潘周聃和南方财经记者聊起了来到粤港澳大湾区的感受。 从上半年携一众企业密集"北上"揽才，到年中面向海外名校博士定向抛出橄榄枝，广东迎接产业变革浪潮的"人才网"正持续织密。 此次与潘周聃一起来到广州，参加"湾有引力·粤聚优才"2025年暑期硕博学子研学走进湾区系列活动（第三期）的海归学子共有50位，其中25位学 子来自牛津大学，7位来自剑桥大学，专业和研究方向涵盖人工智能、生物医药、计算机、工程科学等多个热门领域。 （原标题：牛津、剑桥都到"湾里来"！海归博士"心动"大湾区） 这也是今年广东再次发力"百万英才汇南粤"行动计划，通过举办主题沙龙、名企走访、院士峰会以及现场招聘会等系列研学活动，将人才需求"橄 榄枝"精准抛向牛津、剑桥等境外名校博士群体。 南方财经记者郑玮、实习生苏磊 广州报道 ...

金融界2025年8月21日消息，中欧医疗创新股票A(006228) 最新净值1.7589元，增长1.45%。该基金近1个 月收益率7.35%，同类排名796|1025；近6个月收益率47.02%，同类排名31|986；今年来收益率69.16%， 同类排名25|976。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed Fund C, which has shown significant growth in recent months and year-to-date [1] - As of August 21, 2025, the latest net value of the fund is 2.2560 yuan, reflecting a growth of 2.23% [1] - The fund's one-month return is 6.73%, six-month return is 69.34%, and year-to-date return is 90.32%, with respective rankings of 4351 out of 4701, 29 out of 4538, and 33 out of 4492 in its category [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed Fund C account for a total of 62.83%, with significant positions in companies such as Innovent Biologics (8.33%), Kelun-Biotech (8.15%), and Hengrui Medicine (8.08%) [1] - The fund was established on October 30, 2020, and as of June 30, 2025, it has a total scale of 2.686 billion yuan [1] - The fund manager, Zheng Ning, has a background in stock research and has held various positions in asset management companies before joining Zhongyin Fund Management in 2022 [2]

Core Viewpoint - The Hong Kong stock market experienced a slight decline on August 21, while the innovative drug sector showed resilience, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 1.12% after two consecutive days of decline, indicating a potential recovery in this sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) had a trading volume of 389 million yuan, ending the day with a price increase of 1.12% [1]. - The index tracked by the ETF has a price-to-sales ratio of 3.59, which is significantly lower than that of U.S. biotech indices, suggesting attractive valuation levels [5]. - The index has shown a cumulative increase of 101.58% year-to-date as of July 31, outperforming other indices such as the Hang Seng Index and the Hang Seng Tech Index by 78.08% and 79.53% respectively [9]. Group 2: Industry Trends - The innovative drug sector is experiencing increased volatility, primarily due to previous gains and short-term market divergences, but long-term factors are contributing to a high level of certainty in this sector [3]. - The Chinese government has established a comprehensive policy framework to support the innovative drug industry, emphasizing the creation of a globally competitive innovation ecosystem [3]. - In the first half of 2025, the National Medical Products Administration approved 43 innovative drugs, marking a 59% increase year-on-year, nearing the total of 48 approvals for the entire year of 2024 [4]. Group 3: Company Performance - Leading innovative drug companies, such as BeiGene, have reported a turnaround in profitability, indicating a shift from a focus on research and development to realizing value [3]. - The innovative drug sector is expected to benefit from increased external licensing transactions, with the total licensing amount exceeding $60.8 billion in the first half of 2025, indicating a strong growth trajectory [3]. - The innovative drug industry is entering a new phase characterized by qualitative improvements, with major firms expected to continue delivering strong earnings and growth [7].

Core Insights - The Ping An Medical Health Mixed Fund C (020137) has a latest net value of 2.9022 yuan, reflecting a growth of 1.74% [1] - The fund's performance over the past month shows a return of 1.41%, ranking 681 out of 709 in its category; over the past six months, it has achieved a return of 64.61%, ranking 3 out of 687; and since the beginning of the year, it has returned 87.46%, ranking 6 out of 685 [1] Fund Holdings - The top ten stock holdings of the Ping An Medical Health Mixed Fund C account for a total of 75.91%, with the largest positions being: - Genscript Biotech (10.55%) - Innovent Biologics (9.08%) - CanSino Biologics (8.97%) - BeiGene (7.58%) - Kelun-Biotech (7.54%) - EdiGene (7.49%) - Boli Tianheng (6.34%) - Aier Eye Hospital (6.25%) - Zai Lab (6.13%) - Ascletis Pharma (5.98%) [1] Fund Manager Profile - Zhou Sicong, the fund manager, holds a master's degree in finance from Renmin University of China and has previously worked as a fund manager at YinHua Fund Management Co., Ltd. and Changsheng Fund Management Co., Ltd. She joined Ping An Fund Management Co., Ltd. in May 2023 [2]

（来源：ETF炼金师） 近期，港股市场的创新药板块引发了投资者的广泛关注。特别是在恒生科技（互联网）ETF的前景下， 投资者对港股创新药的前景充满期待。在分析这一领域的动态时，需要明确投资的时间框架，是中长线 投资还是短线交易。 在中长线投资的视角下，港股的医药企业的中期财报和政策面表态显得尤为重要。近期，恒瑞医药的中 报显示出积极的现金流状况，尽管其股价在港股市场表现平平，但相较A股已存在10%的溢价。此外， 药明生物和药明合联等CXO企业的中报也亮眼，受到了外资投行的积极评价，这表明外资对当前市场 的价值认可与信心。 然而，并非所有企业的表现都如预期，率先披露的再鼎医药虽然减亏，但未能达到市场预期，导致其股 价在短期内受到打压。市场普遍处于中报观望期，龙头企业如信达、百济、石药和康方等将在未来几天 集中发布财报，投资者需保持警惕。 针对短线交易的策略，外资的态度和市场资金的共识是关键。港股医药板块的定价权主要掌握在外资手 中，外部环境的稳定与否将直接影响投资者的操作策略。如果外资对创新药板块失去兴趣，可能会带来 整体的抛压，但目前并没有明显迹象表明外资会撤离。 在技术面分析中，近期资金的流入情况显示出稳健 ...

Core Viewpoint - The Hong Kong stock market's AI healthcare sector is experiencing significant activity, with notable gains in various stocks and ETFs, particularly driven by the performance of Ping An Good Doctor [1] Group 1: Market Activity - The Hong Kong Medical ETF (159366) saw an intraday increase of over 2%, with constituent stocks like Ping An Good Doctor (01833) rising over 15% and Kingsoft Biotech (01548) increasing by 6.24% [1] - The trading volume for the Hong Kong Medical ETF reached 235 million yuan, with a turnover rate of 73.21% [1] - Over the past week, the average daily trading volume for the Hong Kong Medical ETF was 381 million yuan [1] Group 2: Company Performance - Ping An Good Doctor reported a total revenue of 2.5 billion yuan for the first half of 2025, marking a year-on-year growth of 19.5%, and a net profit of 134 million yuan, a significant increase of 136.8% [1] - The company's F-end and B-end business segments saw a revenue increase of 30.2%, with the overall number of paying users rising by 35.1% [1] Group 3: AI Investment and Innovation - Ping An Good Doctor is heavily investing in AI, with successful product developments such as "Ping An Xinyi" and "An Director," which enhance the company's service offerings and operational efficiency [2] - The company has established a top-tier medical network to support its AI products, which assist in patient consultations and follow-ups [2] Group 4: Industry Trends - JD Health reported a revenue of approximately 35.29 billion yuan for the first half of 2025, reflecting a year-on-year increase of 24.5%, with AI playing a crucial role in enhancing healthcare services [3] - The Chinese government has reinforced its support for AI in healthcare, which is expected to accelerate the commercialization of AI applications in the sector [3] Group 5: Index Composition - As of July 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index accounted for 58.42% of the index, including major players like WuXi Biologics (02269) and JD Health (06618) [4]

Core Viewpoint - The A-share market has shown a clear bullish trend in 2023, with significant index breakthroughs, leading to impressive performance from many equity fund managers [4][5]. Group 1: Fund Manager Performance - As of August 15, 2023, there are 1,794 public fund managers with performance data, with the majority being new generation managers, achieving an average return of 20.68% for their equity funds [5]. - The performance of fund managers is categorized into three generations: - New Generation (less than 5 years): 901 managers, average return of 20.68% [5]. - Middle Generation (5-10 years): 635 managers, average return of 18.09% [5]. - Old Generation (10 years and above): 258 managers, average return of 16.78% [5]. - The total assets under management (AUM) for these fund managers amount to 55,735.04 billion [5]. Group 2: Top Fund Managers - The top five fund managers from the new generation include: - Liang Furui from Changcheng Fund with a return of 137.72% and AUM of approximately 1.1 billion [6][8]. - Chu Kefa and Ren Jie from Yongying Fund with returns of 122.30% and 108.97% respectively [6][9]. - The top five fund managers from the middle generation include: - Leng Wenpeng from CITIC Construction Investment Fund with a return of 104.73% and AUM of nearly 300 million [10][12]. - The top five fund managers from the old generation include: - Zhou Sicong from Ping An Fund with a return of 90.96% and AUM exceeding 3 billion [13][15]. Group 3: Investment Strategies - Liang Furui employs a unique three-cycle strategy focusing on demand and matching companies with demand cycles, particularly in the innovative drug sector [8]. - Chu Kefa combines quantitative risk control with active stock selection, favoring leading commercial companies and those with technological breakthroughs [9]. - Leng Wenpeng focuses on "specialized, refined, unique, and innovative" companies listed on the Beijing Stock Exchange [12]. - Zhou Sicong emphasizes a three-dimensional screening approach for innovative drug investments, predicting significant industry growth in 2025 [16].

Core Viewpoint - The Hong Kong stock market shows mixed performance, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rebounding after two days of decline, indicating strong investor interest and significant capital inflow [1][8]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) experienced a nearly 1% increase, with trading volume surpassing 1.1 billion HKD, and a net inflow of 32 million HKD on the day, marking 23 consecutive days of net inflow, totaling over 1 billion HKD in the last 20 days [1]. - As of August 19, the latest scale of the Hong Kong Stock Connect Innovative Drug ETF (159570) exceeded 16.5 billion HKD, leading in both scale and liquidity [1]. Group 2: Stock Performance - Most constituent stocks of the Hong Kong Stock Connect Innovative Drug ETF (159570) showed positive performance, with notable increases including Rongchang Bio up over 4%, and several others like Yuanda Pharmaceutical and King’s Ray BioTech up over 3% [3]. - A detailed performance table shows various stocks with their respective changes, highlighting the mixed performance across the sector [4]. Group 3: Company Financials - H Company reported a significant increase in its financial performance for the first half of 2025, achieving a revenue of 15.76 billion CNY, a year-on-year growth of 15.88%, and a net profit of 4.45 billion CNY, up 29.67% [4][6]. - The company’s operating cash flow reached 4.3 billion CNY, reflecting a 41.80% increase, with R&D investment totaling 3.87 billion CNY, of which 3.23 billion CNY was capitalized [6][7]. Group 4: Market Outlook - The outlook for the Hong Kong stock market remains optimistic, with improving profitability in the innovative drug sector and a high earnings forecast rate, suggesting a potential lead over A-shares in the upcoming market cycle [8]. - The introduction of a new initial review directory for innovative drugs by the National Healthcare Security Administration is expected to provide additional growth opportunities, with 121 out of 141 drug names passing the initial review [9]. Group 5: Upcoming Events - The 2025 World Lung Cancer Conference (WCLC) is scheduled for September 6-9 in Barcelona, which will showcase significant research outcomes from domestic innovative drugs [5][9].

Core Viewpoint - The Hong Kong biopharmaceutical stocks experienced a general increase, driven by government support for the industry, particularly emphasized by Premier Li Qiang during his recent visit to Beijing [1] Industry Summary - The biopharmaceutical sector in Hong Kong saw significant stock price increases, with notable gains including 5% for Fuhong Hanlin, 3.6% for King’s Ray Biopharmaceutical, and over 3% for WuXi AppTec [1] - Premier Li Qiang highlighted the need for enhanced high-quality technological supply and policy support to promote the development of the biopharmaceutical industry, aiming to produce more high-quality and efficient new drugs [1] - Continuous high-level endorsements from the government signal a strong commitment to supporting the biopharmaceutical industry, especially in the current economic context [1] Company Summary - Fuhong Hanlin (02696) latest price: 83.000, change: +5.06% [1] - King’s Ray Biopharmaceutical (01548) latest price: 17.940, change: +3.64% [1] - WuXi AppTec (02268) latest price: 59.600, change: +3.38% [1] - Other companies with notable increases include: - Keren Biotechnology (06990) +3.29% - Kangfang Biopharmaceutical (09926) +2.83% - Rongchang Biopharmaceutical (09995) +2.87% - Junshi Biosciences (01877) +2.69% - BeiGene (06160) +2.60% [1]